deltatrials
Active Not Recruiting PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT02889523

Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy (Epi-RCHOP)

A Phase Ib-II Study of Tazemetostat (EPZ-6438) in Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL) or High Risk Follicular Lymphoma (FL) Patients Treated by R-CHOP

Sponsor: Epizyme, Inc.

Conditions DLBCL Follicular Lymphoma Lymphoma
Interventions Cyclophosphamide Doxorubicin Prednisolone Rituximab Tazemetostat Vincristine
Updated 16 times since 2017 Last updated: Oct 8, 2024 Started: Oct 31, 2016 Primary completion: Jan 31, 2023 Completion: Apr 30, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on DLBCL and Follicular Lymphoma, this trial is ongoing. The trial is conducted by Epizyme, Inc. and has accumulated 16 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Aug 2017 · 7 months · monthly snapshot~Aug 2017 – ~Jun 2018 · 10 months · monthly snapshot~Jun 2018 – ~Jul 2019 · 13 months · monthly snapshot~Jul 2019 – ~Nov 2020 · 16 months · monthly snapshot~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Sep 2021 · 7 months · monthly snapshot~Sep 2021 – ~Sep 2022 · 12 months · monthly snapshot~Sep 2022 – ~Feb 2023 · 5 months · monthly snapshot~Feb 2023 – ~Apr 2023 · 59 days · monthly snapshot~Apr 2023 – ~Jul 2024 · 15 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~Sep 2025 · 10 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2025 — Present [monthly]

    Active Not Recruiting PHASE1/PHASE2

  2. Nov 2024 — Sep 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  3. Sep 2024 — Nov 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  5. Apr 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

▶ Show 11 earlier versions

  1. Feb 2023 — Apr 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  2. Sep 2022 — Feb 2023 [monthly]

    Recruiting PHASE1_PHASE2

  3. Sep 2021 — Sep 2022 [monthly]

    Recruiting PHASE1_PHASE2

  4. Feb 2021 — Sep 2021 [monthly]

    Recruiting PHASE1_PHASE2

  5. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE1_PHASE2

  6. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Suspended → Recruiting

  7. Nov 2020 — Dec 2020 [monthly]

    Suspended PHASE1_PHASE2

  8. Jul 2019 — Nov 2020 [monthly]

    Suspended PHASE1_PHASE2

  9. Jun 2018 — Jul 2019 [monthly]

    Suspended PHASE1_PHASE2

    Status: Recruiting → Suspended

  10. Aug 2017 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  11. Jan 2017 — Aug 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Oct 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Epizyme, Inc.
  • The Lymphoma Academic Research Organisation
Data source: The Lymphoma Academic Research Organisation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Argenteuil, France , Avignon, France , Besançon, France , Bordeaux, France , Brussels, Belgium , Chambéry, France , Clermont-Ferrand, France , Créteil, France , Dijon, France , Grenoble, France and 20 more locations